Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc (NQ: BEAM )

43.85 -0.59 (-1.33%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 444,230
Open 45.23
Bid (Size) 42.70 (1)
Ask (Size) 44.70 (1)
Prev. Close 44.44
Today's Range 42.89 - 45.48
52wk Range 27.77 - 80.00
Shares Outstanding 70,468,961
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
A New Bull Market Is Coming: 3 Stocks That Could Skyrocket
Aggressive investors should check out these stocks. 
Via The Motley Fool
3 Stocks That Could Create Lasting Generational Wealth
Making money that spans generations requires thinking big. 
Via The Motley Fool

Performance

YTD
+17.50%
+17.50%
1 Month
+15.15%
+15.15%
3 Month
-7.78%
-7.78%
6 Month
-35.33%
-35.33%
1 Year
-34.17%
-34.17%

More News

Read More
Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones
From Beam Therapeutics
Via Globe NewsWire
Cathie Wood Gets Elon Musk's Attention Over Gene-Editing Therapy Potential: 'Investors Chased The Dream Then. Now, They're Running Away'
Via Benzinga
Beam Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Beam Therapeutics
Via Globe NewsWire
4 Analysts Have This to Say About Beam Therapeutics
Via Benzinga
BMO Capital Upgrades Beam Therapeutics: Here's What You Need To Know
Via Benzinga
Beam Therapeutics's Return On Capital Employed Insights
Via Benzinga
3 Under-the-Radar Biotech Stocks to Buy in 2022
Via The Motley Fool
Analyst Beefs Up Beam Therapeutics Price Target, Says 'Reward Is Now Skewed To Upside'
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022
Via Benzinga
Beam Therapeutics Temporarily Retreats Clinical Plans For Second Sickle Cell Gene Therapy
Via Benzinga
Tesla To $285? Here Are 10 Other Price Target Changes For Tuesday
Via Benzinga
7 ‘Next Big Things’ for Investors to Buy for 2023
Via InvestorPlace
Beam Therapeutics Presents First In Vivo Proof of Concept Preclinical Data on Multiplex Base Edited ESCAPE Platform for Non-Genotoxic Conditioning Regimen for Patients with Sickle Cell Disease Ahead of Autologous Transplant
From Beam Therapeutics
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2022
Via Benzinga
Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022
From Beam Therapeutics
Via Globe NewsWire
BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts
Via Benzinga
Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201
From Beam Therapeutics
Via Globe NewsWire
Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference
From Beam Therapeutics
Via Globe NewsWire
A Sitcom Character Inspired This Investor
Via The Motley Fool
Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease
From Beam Therapeutics
Via Globe NewsWire
Unity Software, Amazon, Doximity And Other Big Gainers From Friday
Via Benzinga
Beam Therapeutics to Participate in Upcoming Investor Conferences
From Beam Therapeutics
Via Globe NewsWire
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.